Altimmune, Inc. ALT

ALT Company Overview

Altimmune, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapeutics for obesity, metabolic disease, and liver disease. The company’s lead programs are centered on peptide-based and incretin-related therapies designed to address large unmet medical needs in cardiometabolic health. Altimmune operates within the biotechnology and pharmaceutical industries, with a primary emphasis on drug discovery, clinical development, and commercialization planning for novel biologic candidates. Its core value proposition is built around differentiated metabolic therapies intended to improve efficacy, tolerability, and patient outcomes relative to existing treatment options.

The company’s principal revenue drivers historically have included government-supported research contracts, licensing activity, and financing transactions, as Altimmune remains a development-stage enterprise without a broadly commercialized product portfolio. Over time, the company evolved from a broader immunotherapeutics and vaccine platform business into a concentrated metabolic disease developer. This strategic shift accelerated following clinical prioritization of obesity and nonalcoholic steatohepatitis (NASH)-related programs, particularly its GLP-1/glucagon dual receptor agonist platform.